USPTO serial 88365991
Q-CARD
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 8, 2022
- Examiner
- LAPTER, ALAIN J
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with Q-CARD?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Monmouth Junction, NJ, US
Monmouth Junction, NJ, US
Monmouth Junction, NJ, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Xiongying Tu
Xiongying Tu Schwabe, Williamson & Wyatt, P.C.1211 SW 5th Ave., Suite 1800Portland, OR 97204United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Assays for research purposes; Biological and chemical reagents used for non-medical research and laboratory purposes, in vitro and in vivo scientific use, the testing of bodily fluids, and the detecting and analyzing of cells, proteins, small molecules, and nucleotides; Biological and chemical test kits comprised of biological, chemical, or diagnostic reagents for the detection and identification of nucleic acids, namely, DNA and RNA in a sample, for laboratory and research use | ACTIVE | Sep 1, 2022 |
| 005 | Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents and assays for testing cells, proteins, small molecules, nucleotides, and nucleic acids; Medical diagnostic reagents; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancers, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, and genetic diseases; Diagnostic biomarker reagents for medical purposes; Biological and chemical test kits for personal wellness in the nature of diagnostic test kits consisting primarily of medical diagnostic reagents and assays for testing of bodily fluids and substances extracted from bodily fluids, namely, cells, proteins, small molecules, nucleotides, and nucleic acids for use in disease detection, namely, cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, and genetic diseases | ACTIVE | Sep 1, 2022 |
| 010 | Medical diagnostic apparatus for testing cells, tissue, biomolecules, proteins, small molecules, and nucleotides; Medical devices for obtaining bodily fluid samples; Medical diagnostic instruments for the analysis of bodily fluids; Medical apparatus for diagnostic use, namely, medical apparatus for diagnostic testing of health conditions, diseases, or abnormalities, namely, in the fields of cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, genetic diseases, and endocrine diseases, and other tissue-based diagnostic testing, cytology, and cell based testing; Medical apparatus, devices, and instruments for wellness testing, health condition testing, and healthcare testing, namely, point-of-care diagnostic devices, at-home diagnostic devices, and portable health monitoring devices that detect health conditions and diseases in the nature of cancers, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases and genetic diseases; Medical apparatus, devices, and instruments for the detection and identification of nucleic acids, namely, DNA and RNA in a sample, in the nature of apparatus for DNA and RNA testing for medical purposes | ACTIVE | Sep 1, 2022 |
| 042 | Scientific laboratory services, namely, detection and identification of cells, proteins, small molecules, and nucleotides in a sample for scientific, research, and technological purposes; Medical laboratory services, namely, providing medical diagnostic assays and diagnostic and prognostic testing for medical research purposes of infectious and residual disease, and the analysis, evaluation, and reporting of those test results to help healthcare professionals for research purposes; Development of new technology for others in the fields of biotechnology, DNA, RNA, small molecules, proteins, and nucleotide analysis services for scientific research purposes; Providing medical and scientific research information in the field of clinical trials, assays and assay development, diagnostics, cancer, RNA, DNA, small molecules, proteins, and nucleotides; Research and development in the medical and digital diagnostics and biotechnology fields; Custom design and development of chemical reagents and biochemical assays; Laboratory research in the field of oncology, hematology, and infectious diseases | ACTIVE | Sep 1, 2022 |
| 044 | Medical services; Medical assistance; Medical consultations; Medical counseling; Medical information; Medical services, medical assistance, medical consultations, medical counseling, medical information, healthcare testing in the nature of the diagnosis of diseases, namely, cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, and genetic diseases, diagnostic testing, namely, medical testing for diagnostic purposes, and wellness services, namely, providing wellness information in the fields of health and wellness, all of the foregoing in the fields of cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, genetic diseases, and other tissue-based diagnostic testing, cytology, and cell-based testing; Medical services for the detection and identification of cells, proteins, small molecules, and nucleic acids in a sample in the nature of medical testing for diagnostic or treatment purposes | ACTIVE | Sep 1, 2022 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Essenlix Corporation
- Other trademarks owned by Essenlix Corporation
- Other trademarks owned by Essenlix Corporation
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named Q-CARD
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 3, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 3, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 3, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 3, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 3, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 8, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Nov 8, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 1, 2022 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Sep 30, 2022 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Sep 23, 2022 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Sep 23, 2022 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Sep 12, 2022 | IUAF | USE AMENDMENT FILED | — |
| Sep 12, 2022 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Mar 12, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 10, 2022 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Mar 10, 2022 | EXT4 | SOU EXTENSION 4 FILED | — |
| Mar 10, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 11, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 9, 2021 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Sep 9, 2021 | EXT3 | SOU EXTENSION 3 FILED | — |
| Sep 9, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 3, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 1, 2021 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Mar 1, 2021 | EXT2 | SOU EXTENSION 2 FILED | — |
| Mar 1, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 3, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 1, 2020 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Sep 1, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| Sep 1, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 10, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 14, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 14, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 25, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 10, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 10, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 10, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 10, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 10, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 13, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 13, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 13, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 11, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 19, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 4, 2019 | NWAP | NEW APPLICATION ENTERED | — |